1. Yin, Z. et al. Invasive pneumococcal disease among HIV-positive individuals, 2000–2009. AIDS Lond. Engl. 26, 87–94 (2012).
2. Thio, C. L. et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort study (MACS). Lancet Lond. Engl. 360, 1921–1926 (2002).
3. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2022. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf
4. Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. Interim Clin. Consid. Use COVID-19 Vaccines Curr. Approv. Auth. U. S. 2023. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html
5. Jensen, C. P. R., Warshawsky, B., Krishnan, R., Wong, E., Zafack, J., Salvadori, M. I., Forbes, N., Abrams, E., Young, K., Tunis, M. C., Wilson, S., Harrison, R., Deeks, S. & On behalf of the National Advisory Committee on Immunization (NACI). COVID-19 vaccines: Canadian Immunization Guide 2023. (accessed Nov 1 2023) https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html#a6.4